Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,110.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-More concerns on Southern Europe banks

Tue, 01st Sep 2020 11:12

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

MORE CONCERNS ON SOUTHERN EUROPEAN BANKS (1012 GMT)

Policy response from governments and the European central bank has been strong, the EU
Recovery fund was a major milestone supporting the sector, but most Southern Europe bank shares
are already fully valued, according to some analysts.

Today Europe’s banks are down 1.7%, while the STOXX 600 index is flat with the tech sector
leading gains up 1.5%.

“We would argue the 'value' argument across some names is now is less clear-cut,” a
Jefferies research report says.

The main issue is the economic impact of the second wave of coronavirus infections which has
hit Europe as “the mid-term outlook remains challenged and, despite some pick-up in inflation
expectations, Euribor rates and futures continue to move lower,” it adds.

“While we are broadly aligned with consensus profit expectations in 2022 (on average), we
sit around 10% below consensus on 2022 pre-provision numbers which tempers our enthusiasm.”

Jefferies top picks are Intesa Sanpaolo, Caixabank and Bankia, while the
broker continues to like Unicaja.

(Stefano Rebaudo)

*****

STOXX 600 DOWN? BLAME THE BRITS! (0912 GMT)

There's no need to beat around the bush: if the STOXX 600 is slightly down (-0.1%) this
morning it's all because of London-listed stocks.

Quite striking how the first 32 losers on the pan-European index are ALL London-listed:

As put by AJ Bell analyst Russ Mould, the FTSE "was nursing a hangover after the Bank
Holiday" and was down over 1.3%.

"Not helping the FTSE’s cause was strength in sterling relative to the dollar, a currency
move which impacts the relative weight of the overseas earnings which dominate the index", Mould
added.

Looking at other European bourses, Germany's DAX is doing quite well, up 0.4% and Milan's
FTSE MIB is still in positive territory.

But looking at 2020 so far this year, the underperformance of the FTSE 100 is becoming a key
feature of the COVID-19 vintage.

Here's the FTSE 100 (blue) against the EURO STOXX 50 and the S&P 500:

(Julien Ponthus)

*****

OPENING SNAPSHOT: TECH AND HEALTH CARE SECTORS LEAD GAINS (0728 GMT)

Tech shares, particularly iPhone suppliers, are leading gains in the European stock market
after a press report that Apple Inc has asked suppliers to make at least 75 million 5G
iPhones for later this year, along with new Apple Watch models, a new iPad Air and a smaller
HomePod.

Among Apple suppliers Dialog Semi stocks are up 2.2%, STMicro shares rise
1%, Infineon shares up 1.6%.

The STOXX 600 index is up 0.7% with the tech sector up 1.5%. The healthcare sector is rising
1.2% after AstraZeneca said they could have data to ask U.S. emergency use authorization
or approval of their COVID-19 vaccines in the short term.

Risk sentiment is supported by a strong survey from China, while concerns about pandemic
trajectories continue to weigh. Travel and leisure stocks are the worst performers
sliding 1%, banks continue to lag behind, down 0.2%.

(Stefano Rebaudo)

*****

ON THE RADAR: ASTRAZENECA, APPLE SUPPLIERS, SUEZ

European equities are set to open higher after yesterday’s fall as a strong survey from
China propped up risk sentiment across Europe.

Apple suppliers look poised to gain on report that the world's largest company has
asked suppliers to make at least 75 million 5G iPhones for later this year. Dialog Semi
, STMicro, Infineon and other European chipmakers under spotlight.

Encouraging news on the coronavirus front as AstraZeneca, which is working with
Oxford University researchers, and Pfizer with partner BioNTech, said they
could have data by October to support U.S. emergency use authorization or approval of their
vaccines.

Meanwhile, Sanofi shares could come under pressure after the French pharma major
said its Kevzara drug trial didn't meet main goal in Covid-19 study.

In other key French moves, Suez, which saw its shares rise around 25% after
yesterday’s Veolia offer, said an unsolicited takeover approach carried "great
uncertainties" and it reiterated its confidence as an independent company.

Vivendi and activist fund Amber Capital - the two biggest shareholders in French
company Lagardere - said they would go to court over Lagardere's refusal to hold a
special shareholders meeting.

Roche received approval from the United States Food and Drug Administration for its
Cobas qualitative testing systems to confirm HIV diagnosis.

Apple suppliers

Seadrill proposed to creditors to turn over its stakes in oil services firms
Archer and Seadrill Seabras to redeem its outstanding secured notes.

Shares in Rocket Internet are up 2.6% in premarket trade after the company
announced a delisting plan.

(Stefano Rebaudo)

*****

MORNING CALL: IN THE BLACK BUT WITH VIRUS CONCERNS (0533 GMT)

European stock futures are in the black this morning along with their U.S. peers, but
concerns about the economic impact of the pandemic after the summer break are still in place.

China's factory activity which expanded at the fastest clip in nearly a decade in August,
bolstered by the first increase in new export orders this year, is supporting risk sentiment in
the continent after driving Asian shares in positive territory.

Expectations of long-lasting fiscal and monetary stimulus are also propping up equities, but
pandemic trajectories are expected to be the main investors focus in the fall, at least until a
vaccine is at hand.

(Stefano Rebaudo)

*****

More News
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.